BioSpace News Archive

Diaceutics PLC, (AIM: DXRX), the precision diagnostic commercialization company, today announces research results from its COVID-19 oncology tracker, which shows the impact of the crisis on cancer testing and diagnosis in the US

Collaborative effort identifies 40 cases of COVID-19 across eight countries; outcomes for this high-risk population were reported in the Journal of Cystic Fibrosis

Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that it is launching a limited distribution program for its product candidate, Pear-004, for people living with schizophrenia

As America is painfully learning through the current coronavirus pandemic, reliable testing with quick and accurate results is the key to stopping a disease in its tracks and providing time-sensitive treatment to the afflicted.

Psychemedics Corporation, the world leader and pioneer in detecting drugs of abuse using hair analysis, introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine.

Genespire, a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, announced today the successful close of a €16M Series A financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan

Diatherix Eurofins, a leader in respiratory viral and bacterial testing, announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its SARS-CoV-2 assay.

BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2020 earnings on Wednesday, May 6 at 4:00 PM Eastern Time.

Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, announced today the first reverse total shoulder arthroplasty (rTSA) cases using Equinoxe® with VERASENSE®, a wireless humeral sensor manufactured by OrthoSensor Inc.

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced that beginning today it will offer antibody blood tests to detect an immune response after infection with the COVID-19 virus. Antibody testing and molecular diagnostic testing for COVID-19 are available to healthcare providers nationwide.